NorthWest Biotherapeutics Inc (NWBO)

[trocprofit]

Blinded interim survival data showed the median OS for the intent-to-treat (ITT) population was 23.1 months from surgery. This was an improvement from the median OS for the standard of care. Interestingly, patients with MGMT methylation had a median OS of 34.7 months from surgery with a 3-year survival of 46.4%. Furthermore, there was a population of extended survivors (n = 100) with a median OS of 40.5 months, which will be further analyzed. However, the study did not provide the IDH status of these patients. The adverse events with DCVax®-L were comparable to standard therapy alone. Final results from further analyses and follow-up have not yet been published.

IDH mutation status and data was one of the major delays in getting to data lock.